

Fund Summary

The Rize Medical Cannabis and Life Sciences UCITS ETF (FLWR) seeks to invest in companies that potentially stand to benefit from the increased adoption of cannabis as a medicine, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. FLWR seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Foxberry Medical Cannabis & Life Sciences Index. Notification: Please note that this fund is in the process of closing. Please refer to the [shareholder notice](#) for further details of the closure and the applicable timetable.

Why FLWR?

Favourable Growth Prospects

FLWR is Europe's first truly global medical cannabis ETF, and provides investors with exposure to the global revolution in cannabis-derived medication and wellness products.

ETF	Rize Medical Cannabis and Life Sciences UCITS ETF
Index Name	Foxberry Medical Cannabis & Life Sciences Index
Fund Size (AUM)	\$14,387,215
TER	0.65%

Powered by New Frontier Data®

FLWR is purpose-built in collaboration with New Frontier Data, an independent cannabis research and tech-driven analytics firm based in Washington, D.C., and leverages their unique insights and proprietary classification system of companies that have demonstrable exposure to the emerging medical cannabis and life sciences sector.

Base Currency	USD
Inception Date	12 February 2020
Replication	Physical - Full Replication
UCITS	Yes
ISIN	IE00BJXRZ273
Index Ticker	FXBYFLWR Index

Unconstrained Approach

FLWR's composition transcends classic sector, size and geographic classifications by tracking an emerging theme.

Share Class	USD Accumulating ETF
Exposure	Global Equities
Domicile	Ireland
Fund Type	Irish ICAV


ETF Efficiency

In a single trade, FLWR delivers access to dozens of companies that are favourably positioned to ride the tailwinds of the medical cannabis and life sciences theme.

Issuer	Rize UCITS ICAV
Promoter	ARK Invest International Ltd
Manager/Investment Manager	IQ EQ Fund Management (Ireland) Limited
Depositary/Custodian	Northern Trust Fiduciary Services (Ireland) Limited
SFDR Classification	Article 8
MSCI ESG Rating	BBB

Index Summary

The Foxberry Medical Cannabis & Life Sciences Index provides exposure to companies involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. The index excludes companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol for the recreational consumer market. The index follows a modified liquidity-based weighting scheme where companies with higher liquidity achieve a bigger weight in the index.



Trading Information

Exchange	Currency	ISIN	Sedol	Ticker	Bloomberg Code
Deutsche Borse Xetra	EUR	.IE00BJXRZ273	BJXRZL6	BLUM	BLUM GY
London Stock Exchange	USD	.IE00BJXRZ273	BJXRZC7	FLWR	FLWR LN
London Stock Exchange	GBP	.IE00BJXRZ273	BK5TNN5	FLWG	FLWG LN
SIX Swiss Exchange	CHF	.IE00BJXRZ273	BJXRZF0	FLWR	FLWR SE

Performance Returns



Cumulative	ETF	Index	Difference
YTD	-31.45%	-31.96%	-0.51%
3 Month	-17.85%	-18.21%	-0.36%
1 year	-35.78%	-36.24%	-0.46%
6 Month	-23.11%	-23.40%	-0.29%
Since Inception	-60.02%	-60.22%	-0.20%


Past performance is not a reliable indicator of future results and is not guaranteed. The ETF performance is the NAV per share and is net of all fees.

Performance Returns are as at 30/11/2023


Top 10 Fund Holdings

Scotts Miracle-Gro Class'	18.88%	Biotechnology/Pharma	52.7%
Perrigo Company Limited C	15.73%	Agriculture Tech & Supplies	28.5%
Jazz Pharmaceuticals Plc	15.35%	Big Pharma	18.2%
Revvity Inc	14.19%		
Growgeneration Corp Com	8.41%		
Teva Pharmaceutical Inds	6.21%		
Novartis Ag Sponsored Adr	6.05%		
Abbvie Inc Com	5.98%		
Cara Therapeutics Inc Com	5.58%		
Hydrofarm Hldgs Group Inc	1.20%		

Top 10 Fund Holding and Fund Sector Weights are as at 30/11/2023



Top 10 Countries



****Totals may not sum to 100% due to rounding****

Country Registration




Investment Team

IQ EQ Fund Management (Ireland) Limited is the investment manager for each of the exchange-traded funds (ETFs) issued by Rize UCITS ICAV and is responsible for the day-to-day investment management decisions for this ETF. The team is highly experienced to all aspects relating to the management of a fund portfolio, including the execution of equities, foreign exchange and cash management.

Risk Factors

- All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed.
- FLWR is vulnerable to cyclical declines in the cannabis sector.
- Any change to existing applicable laws or regulations that currently enable companies to engage in cannabis-related business activities ("CRB Activities") would reduce the value of affected companies and FLWR.
- Also, some companies may breach such applicable laws or regulations which may (1) cause them to be de-listed from stock exchanges and/or reduce their market value (and therefore reduce FLWR's value or its ability to realise its investments) and/or (2) mean that capital gains or income derived from such companies cause FLWR and/or FLWR's investors to be in breach of anti-money laundering laws or other laws applicable to them respectively ("Applicable Laws").
- FLWR may have exposure to the recreational consumer market for cannabis even though it does not intend to. This might mean that the capital gains or income derived from companies with this exposure cause FLWR and/or FLWR's investors to be in breach of Applicable Laws.
- A change in any legal requirements relating to funds with cannabis exposure might require the Manager to stop marketing FLWR in certain countries, de-list FLWR's Shares from certain stock exchanges; and/or close FLWR.
- FLWR invests in pharmaceutical companies which may never generate revenue due to clinical trial failures and/or a lack of required approvals for new drugs. Such factors could severely reduce the values of affected companies and FLWR. FLWR also invests in small publicly traded companies which may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies.
- FLWR invests in global equity securities. As such there is a risk of loss arising from exchange rate fluctuations or exchange control regulations.
- Other: (1) Third party service providers (such as the ICAV's depositary) may go bankrupt and fail to pay money due to FLWR or return property belonging to FLWR. (2) If the Index provider stops calculating the Index or if FLWR's license to replicate the Index is terminated, FLWR may have to be closed. (3) It may not always be possible to buy and sell FLWR's Shares on a stock exchange or at prices closely reflecting the Net Asset Value. (4) There is no capital guarantee or protection on the value of FLWR and investors can lose all the capital invested in FLWR. (5) Please refer to the "Risk Factors" section of the ICAV's Prospectus and the Fund Supplement.



Disclaimer

Marketing Communication / Financial Promotion:

Communications issued in the European Economic Area ("EEA"): This marketing communication has been issued by IQ EQ Fund Management (Ireland) Limited ("**IQ EQ**") acting in its capacity as management company of Rize UCITS ICAV ("**Rize ETF**"). IQ EQ is authorised and regulated by the Central Bank of Ireland. IQ EQ is registered in Ireland with registration number 148223.

Communications issued in jurisdictions outside of the EEA: This marketing communication has been issued by ARK Invest International Ltd ("**Rize UK**") which is an Appointed Representative of Aldgate Advisors Limited, a firm authorised and regulated by the Financial Conduct Authority (FCA FRN 763187). Rize UK is registered in England and Wales with registration number 11770079.

This is a marketing communication. This is not a contractually binding document. Please refer to the prospectus and Fund-specific supplement and Key Investor Information Document (the "**KIID**") of the relevant Fund and do not base any final investment decision on this communication alone.

You should seek professional investment advice before making any decision to invest in a Fund.

This marketing communication is not being provided to you on the basis that you are a client of IQ EQ or Rize UK. Neither IQ EQ nor Rize UK is acting on your behalf and neither entity is responsible for providing protections that would otherwise be afforded to clients of IQ EQ or Rize UK. This marketing communication is for information purposes only. Its contents, and the fact of its distribution, do not constitute investment advice, nor do they constitute tax, legal or any other form of advice or service. It does not constitute or form part of any offer to issue or sell, or the solicitation of any offer to buy or sell any investment. It shall not form the basis of, or be relied upon in connection with, any contract. Information and opinions contained herein have been compiled from sources believed to be reliable but neither IQ EQ nor Rize UK nor any of their respective partners makes any representations as to its accuracy or completeness. Any opinions, forecasts or estimates herein constitute a judgement that is subject to change without notice. IQ EQ and Rize UK disclaim all liability and responsibility arising from any reliance placed by any person on the information contained within this marketing communication.

Where past performance and projected performance information is shown, it must be noted that past performance and projected performance is not a reliable indicator of future performance. Simulated past performance does not represent actual past performance and is not a reliable indicator of future performance.

The Rize Medical Cannabis and Life Sciences UCITS ETF replicates the Foxberry Medical Cannabis & Life Sciences Index. An investment in the Fund involves significant risk and is subject to the volatility of cannabis and pharmaceutical stocks and exchange rate fluctuations and you may lose some or all of your capital.

Capital at Risk Warning – Please note that the value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested. If your investment currency is different to the Funds' currency of denomination (USD) or the currencies in which the Funds' assets are denominated (which may be a range of different global currencies), then the return you will get from your investment may increase or decrease as a result of currency fluctuations between your investment currency and such currencies.

The products referred to in this marketing communication are offered by Rize UCITS ICAV ("**Rize ETF**"). Rize ETF is an open-ended Irish collective asset management vehicle which is constituted as an umbrella fund with variable capital and segregated liability between its sub-funds (each, a "**Fund**") and registered in Ireland with registration number C193010 and authorised by the Central Bank of Ireland as a UCITS. Rize ETF is managed by IQ EQ Fund Management (Ireland) Limited ("**IQ EQ**"). The prospectus (including the Fund-specific supplements and other supplements), the KIIDs, the constitutional document of Rize ETF and the latest annual and semi-annual reports of Rize ETF, the latest Net Asset Values of the Funds and details of the underlying investments of the Funds (together, the "**Fund Information**") are available at <http://www.rizeetf.com>. Any decision to invest must be based solely on the Fund Information. Investors should read the Fund-specific risks in Rize ETF's prospectus, Fund-specific supplements and the KIIDs. The indicative intra-day net asset values of the Funds are available at <http://www.solactive.com>.

The Funds are not offered or aimed at residents in any country in which (a) Rize ETF and the Funds are not authorised or registered for distribution and where to do so is contrary to the relevant country's securities laws, (b) the dissemination of information relating to Rize ETF and the Funds via the internet is forbidden, and/or IQ EQ or Rize UK are not authorised or qualified to make such offer or invitation.

The Funds may be registered or otherwise approved for distribution to the public or certain categories of investors in one or more jurisdictions. Where this is the case, a country-specific web page and copies of the Fund Information will be available at <http://www.rizeetf.com>. The fact of such a registration or approval, however, does not mean that any regulator (including the FCA) has determined that the Funds are suitable for all categories of investors.

United Kingdom: This is a financial promotion. For the purposes of the United Kingdom Financial Services and Markets Act 2000 ("**FSMA**"), Rize ETF is a UCITS that has been recognised by the Financial Conduct Authority (the "**FCA**") pursuant to s.264 of the UK Financial Services and Markets Act 2000. The Fund Information is available in English free of charge upon request from the Facilities Agent in the United Kingdom, IQ EQ Fund Management (Ireland) Limited, at Dashwood House, 69 Old Broad Street, London, EC2M 1QS.

Germany: This is a financial promotion. The offering of the Shares of Rize ETF has been notified to the German Financial Services Supervisory Authority (BaFin) in accordance with section 310 of the German Investment Code (KAGB). The Fund Information in English (and the KIIDs in German language) can be obtained free of charge upon request from the Information Agent in Germany, German Fund Information Service UG (Haftungsbeschränkt), at Zum Eichhagen 4, 21382 Brietlingen, Germany.

Switzerland: This is an advertising document. The state of the origin of the fund is Ireland. In Switzerland, the Representative in Switzerland is 1741 Fund Solutions AG, Burggraben 16, CH-9000 St. Gallen. The Paying Agent in Switzerland is Tellico AG, Bahnhofstrasse 4, 6430 Schwyz. The Fund Information may be obtained free of charge from the Representative. Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units in the Fund.

Austria: This is a marketing communication and serves exclusively as information for investors. Under no circumstances may it replace advice regarding the acquisition and disposal of investments which may result in a total loss of the investment. The Fund Information in English (and the KIIDs in German language) can be obtained free of charge upon request from the Paying and Information Agent in Austria, Erste Bank der österreichischen Sparkassen AG, Am Belvedere 1, 1100 Vienna, Austria.

United States: This marketing communication and its contents are not directed at any person that is resident in the United States ("**US person**"), and no offer or invitation is made to any US person to acquire or sell any service, product or security referred to. The provision of any information in this marketing communication does not constitute an offer to US persons to purchase securities.